Literature DB >> 32021575

Monte Carlo study on the secondary cancer risk estimations for patients undergoing prostate radiotherapy: A humanoid phantom study.

Amir Ghasemi-Jangjoo1,2, Hosein Ghiasi1.   

Abstract

AIM: The aim of this study was to estimate the secondary malignancy risk from the radiation in FFB prostate linac-based radiotherapy for different organs of the patient.
BACKGROUND: Radiation therapy is one of the main procedures of cancer treatment. However, the application the radiation may impose dose to organs of the patient which can be the cause of some malignancies.
MATERIALS AND METHODS: Monte Carlo (MC) simulation was used to calculate radiation doses to patient organs in 18 MV linear accelerator (linac) based radiotherapy. A humanoid MC phantom was used to calculate the equivalent dose s for different organs and probability of secondary cancer, fatal and nonfatal risk, and other risks and parameters related to megavoltage radiation therapy. In out-of-field radiation calculation, it could be seen that neutrons imparted a higher dose to distant organs, and the dose to surrounding organs was mainly due to absorbed scattered photons and electron contamination.
RESULTS: Our results showed that the bladder and skin with 54.89 × 10-3 mSv/Gy and 46.09 × 10-3 mSv/Gy, respectively, absorbed the highest equivalent dose s from photoneutrons, while a lower dose was absorbed by the lung at 3.42 × 10-3 mSv/Gy. The large intestine and bladder absorbed 55.00 × 10-3 mSv/Gy and 49.08 × 10-3, respectively, which were the highest equivalent dose s due to photons. The brain absorbed the lowest out-of-field dose, at 1.87 × 10-3 mSv/Gy.
CONCLUSIONS: We concluded that secondary neutron portion was higher than other radiation. Then, we recommended more attention to neutrons in the radiation protection in linac based high energy radiotherapy.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Equivalent dose; Monte Carlo simulation; Prostate radiotherapy; Radiation contamination; Secondary malignancy

Year:  2020        PMID: 32021575      PMCID: PMC6994283          DOI: 10.1016/j.rpor.2019.12.029

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  29 in total

1.  Applying a hypoxia-incorporating TCP model to experimental data on rat sarcoma.

Authors:  Ruggero Ruggieri; Nadejda Stavreva; Stefania Naccarato; Pavel Stavrev
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-21       Impact factor: 7.038

2.  A new analytical formula for neutron capture gamma dose calculations in double-bend mazes in radiation therapy.

Authors:  Hosein Ghiasi; Asghar Mesbahi
Journal:  Rep Pract Oncol Radiother       Date:  2012-05-24

3.  Photoneutron and capture gamma dose equivalent for different room and maze layouts in radiation therapy.

Authors:  Asghar Mesbahi; Hosein Ghiasi; Seyed Rabee Mahdavi
Journal:  Radiat Prot Dosimetry       Date:  2010-01-18       Impact factor: 0.972

4.  Undesirable nuclear reactions and induced radioactivity as a result of the use of the high-energy therapeutic beams generated by medical linacs.

Authors:  Adam Konefal; Kinga Polaczek-Grelik; Wiktor Zipper
Journal:  Radiat Prot Dosimetry       Date:  2007-06-14       Impact factor: 0.972

5.  Monte Carlo based investigations of electron contamination from telecobalt unit head in build up region and its impact on surface dose.

Authors:  A S Jagtap; T Palani Selvam; B J Patil; S T Chavan; S N Pethe; Gauri Kulkarni; S S Dahiwale; V N Bhoraskar; S D Dhole
Journal:  Appl Radiat Isot       Date:  2016-09-12       Impact factor: 1.513

Review 6.  Models for the risk of secondary cancers from radiation therapy.

Authors:  Alexandru Dasu; Iuliana Toma-Dasu
Journal:  Phys Med       Date:  2017-02-24       Impact factor: 2.685

7.  Long-term outcome of eight cats with non-lymphoproliferative nasal tumours treated by megavoltage radiotherapy.

Authors:  R J Mellanby; M E Herrtage; J M Dobson
Journal:  J Feline Med Surg       Date:  2002-06       Impact factor: 2.015

8.  Screening and verifying potential NTCP inhibitors from herbal medicinal ingredients using the LLC-PK1 cell model stably expressing human NTCP.

Authors:  Zhuo-Wei Shen; Meng-Yue Luo; Hai-Hong Hu; Hui Zhou; Hui-Di Jiang; Lu-Shan Yu; Su Zeng
Journal:  Chin J Nat Med       Date:  2016-07

9.  Electron absorbed dose measurements in LINACs by thermoluminescent dosimeters.

Authors:  J Rodríguez Cortés; R Alvarez Romero; J Azorín Nieto; T Rivera Montalvo
Journal:  Appl Radiat Isot       Date:  2013-06-21       Impact factor: 1.513

10.  The impact of PET/CT scanning on the size of target volumes, radiation exposure of organs at risk, TCP and NTCP, in the radiotherapy planning of non-small cell lung cancer.

Authors:  Radovan Vojtíšek; Jan Mužík; Pavel Slampa; Marie Budíková; Jaroslav Hejsek; Petr Smolák; Jiří Ferda; Jindřich Fínek
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.